International Psoriasis Council
Advancing Knowledge. Improving Care.
Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing psoriasis treatment in this IPC-led symposium
Discover expert insights on a recent study analyzing the mental health outcomes of patients with moderate to severe psoriasis treated
Boehringer Ingelheim’s SPEVIGO® is now FDA-approved for generalized pustular psoriasis in adults and pediatric patients aged 12+, with expanded indications
UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the FDA, representing a major milestone in the treatment of adults with moderate
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira®
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib,
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral
The United States Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) granted these designations based on
The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.
Amgen receives approval from the United States Food and Drug Administration (FDA) for AMJEVITA™, a biosimilar for adults with psoriasis
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to
Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.